Cancer Treatment Updates
NCI embraces scientific road map to achieve Cancer Moonshot goals
September 6th, 2016
National Cancer Institute Acting Director Douglas Lowy, M.D., today accepted, with revisions that reflect NCAB’s discussion, the recommendations of a Blue Ribbon Panel (BRP) on 10 approaches most likely to make a decade’s worth of progress against cancer in five years, a key goal of the White House Cancer Moonshot.
Meta-Analysis Finds Benefits of Adjuvant Bisphosphonates for Postmenopausal Breast Cancer
September 8th, 2015
Bisphosphonates can reduce the rate of breast cancer recurrence in bone, according to a meta-analysis of randomized trials of bisphosphonates as adjuvant therapy for women with early-stage breast cancer.Palbociclib Improves Survival in Women with Hormone Receptor-Positive Metastatic Breast Cancer
July 23rd, 2015
An interim analysis of the PALOMA3 trial shows that palbociclib plus fulvestrant extends the progression-free survival of some women with hormone receptor-positive metastatic breast cancer.Pembrolizumab Improves Progression-Free Survival in Patients with Ipilimumab-Resistant Melanoma
July 19th, 2015
Results from the KEYNOTE-002 clinical trial show that pembrolizumab improves progression-free survival in patients with ipilimumab-resistant melanoma.Nivolumab-Based Treatments Delay Progression of Advanced Melanoma
June 25th, 2015
In an international, double-blind, randomized phase III trial, the combination of nivolumab and ipilimumab improved progression-free survival compared with ipilimumab alone for patients with advanced melanoma.Pembrolizumab Improves Overall Survival in Patients with Advanced Melanoma
May 25th, 2015
In a randomized phase III study, pembrolizumab (Keytruda®) improved survival in patients with advanced melanoma compared with Ipilimumab (Yervoy®).Gardasil 9 Vaccine Protects against Additional HPV Types
March 1st, 2015
In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.Gardasil 9 Vaccine Protects against Additional HPV Types
March 1st, 2015
In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.Gardasil 9 Vaccine Protects against Additional HPV Types
March 1st, 2015
In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
January 8th, 2015
Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.